Antigen tests to detect SARS-CoV-2 have emerged as a
promising
rapid diagnostic method for COVID-19, but they are unable to differentiate
between variants of concern (VOCs). Here, we report a rapid point-of-care
test (POC-T), termed CoVariant-SPOT, that uses a set of antibodies
that are either tolerant or intolerant to spike protein mutations
to identify the likely SARS-CoV-2 strain concurrent with COVID-19
diagnosis using antibodies targeting the nucleocapsid protein. All
reagents are incorporated into a portable, multiplexed, and sensitive
diagnostic platform built upon a nonfouling polymer brush. To validate
CoVariant-SPOT, we tested recombinant SARS-CoV-2 proteins, inactivated
viruses, and nasopharyngeal swab samples from COVID-19 positive and
negative individuals and showed that CoVariant-SPOT can readily distinguish
between two VOCs: Delta and Omicron. We believe that CoVariant-SPOT
can serve as a valuable adjunct to next-generation sequencing to rapidly
identify variants using a scalable and deployable POC-T, thereby enhancing
community surveillance efforts worldwide and informing treatment selection.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.